Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Swedish MTP Council made positive recommendations for Prosigna and OncotypeDX

On November 18, 2021, Swedish Medical Technologies Product (MTP) Council published recommendations to the regions regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment. The technologies were evaluated within the Orderly introduction framework, which is a staged process, including horizon scanning, selection of the method for evaluation, the decision on national collaboration, health economic evaluation by the Dental and Pharmaceutical Benefits Agency (TLV), and recommendations by MTP Council to regions about the introduction of the method and criteria for use.

TLV started performing the health economic evaluation in September 2020. Initially, four technologies were included. However, the manufacturer company of EndoPredict (Myriad Genetics) declined to participate in the evaluation. Regarding the MammaPrint by Agendia, the MTP Council cannot currently comment on the product due to insufficient data.

The MTP Council made the following recommendations to the regions:

  • Prosigna can be used before the decision on adjuvant chemotherapy in women with breast cancer when there is uncertainty about the benefit of treatment;
  • OncotypeDX can be used before the decision on adjuvant chemotherapy in women with breast cancer when there is uncertainty about the benefit of treatment provided that handling of personal data can take place in accordance with current Swedish and EU legislation;
  • Currently, refrain from using the EndoPredict and MammaPrint due to lack of requested documentation.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).